On January 6, 2022 Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, reported it will be featured as a presenting company at the H.C. Wainwright Bioconnect Conference (Press release, Nuvo Pharmaceuticals, JAN 6, 2022, https://www.miravohealthcare.com/news/miravo-healthcare-announces-participation-at-the-h-c-wainwright-bioconnect-conference/ [SID1234598346]). The conference is being held as a virtual conference on January 10-13, 2022.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Jesse Ledger, Miravo’s President & Chief Executive Officer and Mary-Jane Burkett, Miravo’s Vice President & Chief Financial Officer, will be providing an overview of the Company’s business during the presentation. If you are an institutional or retail investor and would like to listen to the Company’s presentation, please click on the following link (View Source) to register for the conference. Corporate presentations and panels are available live and on-demand on January 10, 2022, starting at 7:00 a.m. ET.
Event: H.C. Wainwright Bioconnect Conference (Virtual Conference)
Date: January 10-13, 2022
Time: Available for on-demand viewing starting at 7:00 a.m. ET January 10th
Company Webcasting Link: View Source
About H.C. Wainwright & Co.
H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998. For more information visit H.C. Wainwright & Co. on the web at www.hcwco.com.